NASDAQ:MIST
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. reported net income of −$63.1M in fiscal 2025. Free cash flow was −$49.3M.Summary generated from Milestone Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−146.3%
Return on equity−229.7%
Debt / equity1.37
Free cash flow−$49.3M
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −43 | −60 | −61 | −42 | −62 |
| Net income | −43 | −58 | −60 | −42 | −63 |
| Free cash flow | n/a | −53 | −47 | −29 | −49 |
Recent filings
- 8-KOther events
Sep 3, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KDirector or officer change
Jun 15, 2026 - 4Insider transaction report
Jun 12, 2026 - 4Insider transaction report
Jun 12, 2026 - 8-KResults of operations and financial condition
May 13, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026